Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals

Product Overview

Capmaxen 200 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Capmatinib. It is listed here as a same-ingredient branded option for people researching Tabrecta, a reference brand associated with Novartis. Capmaxen and Tabrecta must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 200 mg strength.

Capmaxen vs. Tabrecta – Originator / Reference Brand Comparison

Tabrecta is a widely recognized reference brand for Capmatinib associated with Novartis. Capmaxen is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Capmaxen is manufactured by Novartis, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.

Composition and Active Ingredient

Active ingredient: Capmatinib
Strength: 200 mg
Dosage form: Tablet
Pharmacological class: MET inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.

Therapeutic Uses and Indications

Capmatinib is used in selected MET exon 14 skipping non-small cell lung cancer. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.

Mechanism of Action – How Capmatinib Works

Capmatinib is a MET inhibitor. In general, it inhibits MET kinase signaling. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.

Dosage and Administration

The product contains 200 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.

Contraindications

Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.

Warnings and Precautions

Important precautions for Capmatinib include: edema, liver injury and lung inflammation. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.

Possible Side Effects

The adverse-effect profile of Capmatinib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include edema, liver injury and lung inflammation. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.

Drug Interactions

Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Capmatinib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.

Pregnancy, Fertility and Breastfeeding

Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Capmatinib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.

Storage and Handling

Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.

Why Is Capmaxen Listed as an Alternative to Tabrecta?

This listing helps customers identify an Everest Pharmaceuticals product containing Capmatinib while researching Tabrecta. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.

Manufacturer Information

Listed brand: Capmaxen
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Tabrecta
Reference company: Novartis
Generic ingredient: Capmatinib
Strength: 200 mg
Dosage form: Tablet
Therapeutic class: MET inhibitor

Frequently Asked Questions

What is Capmaxen 200 mg?

It is an Everest Pharmaceuticals tablet containing Capmatinib 200 mg.

Is Capmaxen the same as Tabrecta?

They are presented as brands associated with Capmatinib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.

What is Capmatinib used for?

Capmatinib is used in selected MET exon 14 skipping non-small cell lung cancer, subject to the applicable label and clinical assessment.

How does Capmatinib work?

It inhibits MET kinase signaling.

Can I switch strengths or brands myself?

No. A licensed prescriber or pharmacist must assess any substitution.

Is a prescription needed?

Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.

Important Medical Disclaimer

This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.